Brokerage firm Janney Capital Upgrades its rating on Sarepta Therapeutics Inc(NASDAQ:SRPT). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by Janney Capital was issued on Sep 19, 2016.
In a different note, On Sep 14, 2016, Needham said it Maintains its rating on Sarepta Therapeutics Inc. In the research note, the firm Raises the price-target to $26.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 20, 2016, Wedbush said it Reiterates its rating on Sarepta Therapeutics Inc. The shares have been rated ‘Outperform’ by the firm.
Sarepta Therapeutics Inc (SRPT) made into the market gainers list on Thursdays trading session with the shares advancing 8.45% or 4.75 points. Due to strong positive momentum, the stock ended at $60.97, which is also near the day’s high of $61.6. The stock began the session at $56.9 and the volume stood at 1,12,03,556 shares. The 52-week high of the shares is $58.87 and the 52 week low is $8. The company has a current market capitalization of $2,920 M and it has 4,78,99,532 shares in outstanding.
Sarepta Therapeutics Inc(SRPT) last announced its earnings results on Jul 19, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $0.00. Analysts had an estimated revenue of $90.00K. Earnings per share were $-1.19. Analysts had estimated an EPS of $-1.19.
Several Insider Transactions has been reported to the SEC. On Sep 16, 2016, Edward M. Md Kaye (SVP Interim CEO & CMO) sold 24,557 shares at $30.00 per share price.Also, On Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price.On Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.